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Abstract 43 
 44 
Recent studies have generated interest into the function of human adenovirus serotype 5 45 
(HAd-V5) hexon: factor X (FX)-binding and subsequent hepatocyte transduction and 46 
interaction with the immune system. Here, we retargeted adenovirus serotype 5 vectors, 47 
ablated for FX interaction, by replacing amino acids in hexon HVR7 with RGD-4C or 48 
inserting the peptide into the fiber HI loop. These genetic modifications in the capsid were 49 
compatible with virus assembly, and could efficiently retarget transduction of the vector via 50 
the αvβ3/5 integrin-mediated pathway, but did not alter immune recognition by pre-existing 51 
human neutralising anti-HAdV-5 antibodies or by natural antibodies in mouse serum. Thus, 52 
FX-binding ablated HAdV-5 can be retargeted but remain sensitive to immune-mediated 53 
attack. These findings further refine HAd-V5 based vectors for human gene therapy and 54 
inform future vector development. 55 
56 
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Adenoviral (Ad)-based vectors, particularly those based on human adenovirus serotype 5 57 
(HAdV-5) are widely used clinically and experimentally. In vitro, and in local in vivo 58 
applications, HAdV-5 transduces cells via the human coxsackie and adenovirus receptor 59 
(hCAR) (Bergelson et al., 1997, Tomko et al., 1997). Our research has focussed on the use of 60 
adenoviral vectors as a tool for ex vivo manipulation of coronary artery bypass material to 61 
overexpress anti-proliferative genes (e.g. TIMP-3, p53) in coronary artery vascular smooth 62 
muscle cells (VSMCs), to prevent their migration, proliferation and formation of a neointimal 63 
lesion and ultimately graft reocclusion and failure following grafting (George et al., 2011). A 64 
significant limitation in this strategy is that VSMCs express a very low level of CAR and are 65 
thus refractory to transduction (Parker et al., 2013), necessitating high input titers of HAdV-5 66 
to achieve therapeutic levels of transgene expression. For systemic in vivo applications, 67 
HAdV-5 efficiently and selectively transduces hepatocytes (Huard et al., 1995) in a process 68 
mediated though the engagement of the blood coagulation factor X (FX) with the 69 
hypervariable regions (HVR) of the HAdV-5 hexon protein (Hofherr et al., 2008, Kalyuzhniy 70 
et al., 2008, Waddington et al., 2008). Through selective modification of the HVRs, we 71 
previously generated a vector (HAdV-5T*) devoid of FX interactions and consequently 72 
hepatocyte transduction by introducing point mutations in key FX-interacting amino acids of 73 
the hexon protein HVR, namely T270P and E271G (HVR5) and I421G, T423N, E454S, 74 
L426Y and E451Q (all in HVR7) (Alba et al., 2009). Conversely, it has been reported that 75 
FX may actually offer a protective role in gene delivery, by shielding HAdV-5 from immune 76 
mediated attack by natural IgM and the classical complement system (Xu et al., 2013) that 77 
interact with HVRs, neutralising the virus (Ma et al., 2015). The specific amino acids 78 
responsible for immune recognition remain unknown, and the impact in humans remains 79 
unconfirmed. Incorporation of FX binding HVRs from HAdV-5 into HAdV-26 (non-FX 80 
binding Ad serotype) instilled liver transduction to this vector (Ma et al., 2015), reiterating 81 
the importance of FX in determining viral hepatic transduction. Therefore, retargeting of FX-82 
ablated virus remains an area of interest for improving safety and efficacy of gene therapy 83 
vectors.  84 
 85 
In this study, we evaluate optimal locations compatible for inserting targeting peptides within 86 
the HAdV-5T* vector. Previous studies identified the fiber HI loop as viable for peptide 87 
incorporation for retargeting in vitro and in vivo (Krasnykh et al., 1998, Dmitriev et al., 1998, 88 
Reynolds et al., 1999). Furthermore, the incorporation of RGD into HAdV-5 HVR5 was 89 
shown to result in increased transduction in non-permissive VSMC using a non-modified 90 
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HAdV-5 vector with high background hepatocyte transduction (Vigne et al., 1999). Here, 91 
three locations were selected for peptide incorporation: fiber HI loop (after amino acid 92 
543G), and hexon HVRs 5 and 7 (Figs 1a - 1d). We selected the RGD-4C (CDCRGDCFC) 93 
peptide to test retargeting because it efficiently binds to αvβ3 and αvβ5 integrins expressed on 94 
many cell types, including endothelial cells (Zitzmann et al., 2002). This peptide has 95 
previously been widely used for adenoviral retargeting studies (Pasqualini et al., 1997, 96 
Dmitriev et al., 1998). The RGD-4C peptide was inserted into the HVRs with (designated 97 
“R” for replacement) or without (designated “I” for insertion) replacement of amino acids 98 
upstream of amino acid 272C (in HVR5) or 432K (in HVR7) whilst replacements involved 99 
removal of amino acids 272A–280L or 427T–435Q with simultaneous insertion of the 100 
peptide (Figs. 1c and 1d).  101 
 102 
RGD-4C was cloned in modified shuttle plasmids containing the T* modified sequence (Fig. 103 
1b) (Alba et al., 2009) or fiber HI loop (Fig. 1d) (Alba et al., 2010). Vectors were linearised 104 
and electroporated into BJ5183 bacteria cells with digested pAd5CMVlacZ for homologous 105 
recombination. Adenoviral production was performed in HEK293 cells as described 106 
previously (Alba et al., 2009). Peptide insertion in HAdV-5T*HVR7I proved incompatible 107 
with virus assembly, suggesting limitations for peptide insertion within this locale. Virus 108 
generation could be achieved for HAdV-5T*HVR5I, however titer assessment indicated very 109 
poor virus particle: plaque forming unit (vp: PFU) ratios (Fig. 1e), again suggesting simple 110 
insertion strategies within the HVRs appear to limit viral fitness, and this virus was therefore 111 
excluded from subsequent analysis. All other viruses were successfully propagated, verified 112 
by sequencing and quality control demonstrated consistent, high quality virus batches, as 113 
assessed by silver staining, BCA assay, nanoparticle tracking analysis (NanoSight LM10, 114 
Malvern) and plaque forming unit (pfu) assays (Figs. 1e and 1f), thus demonstrating amino 115 
acid removal from HVR5 and HVR7 are non-essential for virus assembly. 116 
 117 
Recombinant viruses were evaluated for cell binding and transduction in αv integrin-positive 118 
SKOV3 cells and A549 cells (Guo et al., 2009, Cannistra et al., 1995). Cells were transduced 119 
with HAdV-5, HAdV-5T* and peptide-modified adenoviral vectors at 50 pfu/cell, and 120 
transduction was assessed 48 hours post-transduction after a 3-hour exposure to each Ad by 121 
measuring β-galactosidase activity using the Tropix Galacton Plus and Tropix accelerator II 122 
kit (Applied Biosystems). Replacement of amino acids in HVR5 with RGD-4C or its 123 
insertion in the HI loop failed to increase cell transduction compared to HAdV-5 or HAdV-124 
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5T*. However, replacing amino acids in HVR7 (HAdV-5T*HVR7R) with RGD4C in the 125 
HAdV-5T* background exhibited >10-fold increase in transduction compared to the parental 126 
HAdV-5T* vector (Figure 2a and 2b), validating HVR7 as a candidate site for targeting 127 
peptide insertion. Strategies to improve vascular tropism for effective gene delivery in 128 
coronary artery bypass graft purposes need to efficiently target VSMC , therefore we tested 129 
viral transduction in low passage (passage 2-5) human saphenous vein (HSV) primary 130 
VSMC, isolated as previously described (Southgate and Newby, 1990). Using the RGD 131 
targeted vectors (500 pfu/cell), we observed a robust 6-fold increase in transduction in HSV 132 
VSMC transduced with HAdV-5T*HVR7R or HAdV-5T*HI loop compared to HAdV-5 or 133 
HAdV-5T*, but not HAdV-5T*HVR5R (Fig. 2c). This contrasts with previous studies 134 
demonstrating insertion of RGD in HVR5 in an otherwise wild type HAdV-5 capsid, which 135 
did increase VSMC transduction (Vigne et al., 1999). This discrepancy could relate to the 136 
different RGD peptide sequence used in each study, our peptide contained 4 cysteine 137 
(CDCRGDCFC) in contrast to only two in the previous study (DCRGDCF) (Vigne et al., 138 
1999). Additionally, these differences may relate to conformation alterations introduced by 139 
the specific combination of the FX-binding ablating mutations engineered in HVR5 140 
combined with the RGD peptide incorporation.  141 
 142 
Surface binding analysis was performed by incubating the recombinant vectors with the cells 143 
at 4°C for 1 hour. DNA was then isolated using QIAamp DNA Mini Kit (QIAGEN) and cell-144 
membrane associated viral genomes were quantified by quantitative PCR as described 145 
previously (Alba et al., 2009). No change in binding was observed for HAdV-5T*HVR5R in 146 
any cell type, compared to HAdV-5T* (Figs. 2d, 2e, 2f), confirming that insertion of peptides 147 
within HVR5 confers little re-targeting benefit, whilst significant increases in cell association 148 
were observed for HAdV-5T*HVR7R (Figs. 2d and 2f). Increased binding to A549 cells was 149 
observed following peptide insertion in the fiber HI loop, although this did not correlate with 150 
increased transgene expression (Figs. 2b and 2e). In HSV VSMC, no increase in binding was 151 
observed for HAdV-5T*HI loop, however transduction was increased (Fig. 2f). This 152 
inconsistency could be due to differences in the ability of the virus to internalise and traffic 153 
through different cellular compartments following uptake. The discrepancy is observed 154 
across all of the cells type tested (SKOV3, A549 and HSV VSMC) indicating that the 155 
insertion of RGD-4C in the fiber HI loop may influence the surrounding capsid structure and 156 
hence effect trafficking to the nucleus. Further studies are required to fully delineate this 157 
finding. 158 
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 159 
FX binding HAdV-5 has been shown to prevent IgM and complement-mediated 160 
neutralization of the virus in vivo (Xu et al., 2013), with inhibitory serum components 161 
binding sites within the HAdV-5 HVRs (1-3 and 5-7) (Ma et al., 2015). We tested if this 162 
response was altered by the insertion of the RGD-4C peptide within these regions by 163 
investigating the sensitivity of the vectors to murine serum in vitro using a snake venom-164 
derived factor X binding protein (X-bp) which binds to the Gla domain of FX preventing its 165 
interaction with Ad hexon (Waddington et al., 2008, Atoda et al., 1998). Recombinant Ad 166 
vectors (2x1010 vp/mL) were incubated with RPMI-1640 media, 90% C57BL/6 mouse serum 167 
or 90% C57BL/6 mouse serum pre-incubated with 40 µg/mL X-bp, for 30 min at 37°C. Ad 168 
vector suspensions were diluted 200-fold in serum-free media and 100 µL added to SKOV3 169 
cells for 2 hours at 37°C before being replaced with RPMI-1640 media with 2% FCS. 170 
Transgene expression was quantified 16 hours post-transduction as relative light units (RLU) 171 
normalized to total protein. HAdV-5 mediated transduction significantly increased in the 172 
presence of serum, and reduced following pre-incubation of serum with X-bp (to bind and 173 
neutralize FX) (Waddington et al., 2008, Mizuno et al., 2001). HAdV-5T* demonstrated 174 
reduced transduction in the presence of murine serum compared to media alone (Fig. 3a). 175 
Peptide insertion failed to prevent virus neutralization and reduction in transduction, 176 
indicating that these sites are not critical to natural antibody mediated binding and 177 
neutralisation (Fig. 3a). To evaluate what effect, if any, peptide insertion might have on 178 
evasion of pre-existing human anti-HAdV-5 immunity, we performed neutralisation assays 179 
on HepG2 cells transduction following incubation with 1,000 vp/cell of Ad vectors in the 180 
presence of 1 IU/mL of FX and in 2.5% serum isolated from 103 cardiovascular patients 181 
(Parker et al., 2009). Reporter gene expression was quantified 48 hours post-transduction, and 182 
the changes in transduction relative to vector in the absence of serum was assessed (Fig. 3b). 183 
Incorporation of RGD-4C peptide into hexon or fiber had no discernible effect on evasion of 184 
pre-existing immunity, with 39.6% evasion observed at the 90% neutralisation level for both 185 
HAdV-5T*HVR7R and HAdV-5T*HI loop compared with 35.9% for the parental HAdV-186 
5T* (Fig. 3b). 187 
 188 
This study successfully retargeted a FX-ablated HAdV-5 vector to human smooth muscle 189 
cells and demonstrates that incorporation of the RGD-4C targeting peptide does not affect 190 
neutralisation by natural antibodies in murine sera or recognition by pre-existing anti-HAdV-191 
5 immunity in the general population. Whilst ablation of FX interactions increases 192 
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neutralisation of Ad via IgM and complement, this has only been demonstrated in murine 193 
models to date (Xu et al., 2013). It remains unclear whether this is replicated in humans and 194 
this will be important to determine in the future. For intravascular delivery applications in 195 
humans, optimised retargeting strategies, including those based upon FX-binding ablated Ad 196 
vectors described herein, will be of key importance. Further studies will be required to  197 
evaluate these vectors in ex vivo human vein culture model (Soyombo et al., 1990) and 198 
suitable in vivo animal models to determine confirm the ability of these modified viruses to 199 
target to vasculature using clinically relevant model systems. 200 
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FIGURE LEGENDS 297 
 298 
Figure 1. RGD-4C peptide placement in HAdV-5T* and quality control analysis of 299 
purified viruses. 300 
(a) Hexon trimer protein, arrows indicate RGD-4C insertion sites in HVR5 (orange) or 301 
HVR7R (blue). (b) HAdV-5 hexon amino acid sequence; HVR5 and HVR7 are highlighted in 302 
grey; T* point mutations are marked with asterisk (*).  The amino acids removed for 303 
generation of RGD-4C replacement vectors are designated by dashed line and RGD-4C 304 
insertion point is indicated by black arrow. (c) Fiber protein, arrows indicate RGD-4C 305 
insertion sites in HI loop (purple). (d) HAdV-5 fiber amino acid sequence; arrow indicated 306 
insertion site of RGD-4C. (e) Details of vector production, indicating preparation in HEK293 307 
cells and infectious titres measured by end-point dilution infection in HEK293 cells, physical 308 
titers quantified by microBCA and nanoparticle tracking analysis (Nanosight) and the 309 
respective VP: pfu ratios for each virus. (f) Analysis of viral proteins by SDS-PAGE and 310 
silver staining. 311 
 312 
Figure 2. Assessment of HAdV-5T* retargeting by cell surface binding and viral 313 
transduction in three cell types.  314 
Cells were transduced with HAdV-5, HAdV-5T* and peptide-modified adenoviral vectors 315 
(HAdV-5T*HVR5R, HAdV-5T*HVR7R and HAdV-5T*HI loop) at a concentration of 50 316 
pfu/cell for SKOV3 and A549 cells and 500 pfu/cell for human saphenous vein vascular 317 
smooth muscle cells (HSV VSMC). (a - c) Transduction was assessed 48 hours post-318 
transduction after a 3-hour exposure to each HAdV by measuring β-galactosidase activity. (d 319 
- f) Surface binding analysis was performed by incubating the HAdV with the cells at 4°C for 320 
1 hour and cell-bound adenoviral vectors were quantified by measuring adenoviral genomes 321 
by quantitative PCR as described in (Alba et al., 2009). Each experiment was performed in 322 
technical triplicate and repeated 3 independent times. Mean ± Standard Deviation One-way 323 
ANOVA with Bonferroni post-hoc analysis performed using Graphpad Prism v.5; *** 324 
p<0.001.  325 
 326 
Figure 3. Evaluation of the effect of peptide insertion on evasion of neutralising anti- 327 
HAdV-5 immunity. 328 
(a) HAdV-5T* and its derivatives (2x1010 vp/mL) were incubated with RPMI-1640 media, 329 
90% C57BL/6 mouse serum or 90% C57BL/6 mouse serum preincubated with 40 µg/mL X-330 
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bp, for 30 min at 37°C. Virus suspensions were diluted 200-fold in serum-free media and 100 331 
µL added to SKOV3 cells for 2 h at 37°C before being replaced with RPMI-1640 media with 332 
2% FCS. Transgene expression was quantified 16 h post-transduction as relative light units 333 
(RLU) normalized to total protein. Transduction expressed as a percentage of control 334 
(HAdV-5 transduction with serum free media alone); each experiment was performed in 335 
technical quadruplicate and repeated two independent times. Mean ± SEM * p<0.05. (b) 336 
Effect of neutralizing sera on HepG2 cells transduction  following incubation with 1,000 337 
vp/cell of HAdV vectors in the presence of 1 IU/mL of FX and 2.5% sera from patients 338 
previously screened for anti-HAdV-5 Nabs (Parker et al., 2009) and stained for β-Gal 339 
expression 48 h post-transduction. Experiment was performed four times, data presented are 340 
mean ± SEM. 341 
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